Teva Provides Update on Generic Aciphex Litigation
Health is a unity and harmony within the mind, body and spirit which is unique to each person, and is as defined by that person. The level of wellness or health is, in part, determined by the ability to deal with and defend against stress. Health is determined by physiological, psychological, socio-cultural, spiritual, and developmental stage variables.
logo - spiritindia - Teva Provides Update on Generic Aciphex Litigation
Home | Cancer | Therapies | Diet | Herbs | Heart | Skin | Cosmetic Surgery | Arthritis | Allergies | Eyes | GIT

Teva Provides Update on Generic Aciphex Litigation

GERD :: Teva Provides Update on Generic Aciphex Litigation

GERD :: Teva Provides Update on Generic Aciphex Litigation

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA)announced that the U.S. District Court for the Southern istrict of New York has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Eisai's acid pump inhibitor Aciphex? (Rabeprazole Sodium) Tablets, 20 mg.

The Court found Eisai's U.S. Patent No. 5,045,552 enforceable. Teva intends to appeal this decision immediately as well as the Court's decision granting to Eisai Summary Judgment of validity.

The FDA has already granted final approval for Teva's Abbreviated New Drug Application (ANDA) for Rabeprazole Sodium Delayed-Release Tablets, 20 mg. As one of the first companies to file an ANDA with a Paragraph IV patent certification, Teva has been awarded 180 days marketing exclusivity for this product, which will start on the earlier of the date of first commercial launch or a final court decision.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.

(GERD :: Teva Provides Update on Generic Aciphex Litigation published at SpiritIndia on Monday, May 14, 2007)

Search more information on GERD

Recently posted related articles on GERD :

  1. GERD :: New studies reveal that night-time acid reflux can impact sleep
  2. Heartburn :: Tips on Heartburn Relief for GERD patients
  3. GERD :: Doctors, engineers develop new wireless system to detect esophageal reflux
  4. GERD :: Southern District Court of New York Rules Patent for ACIPHEX Enforceable
  5. GERD :: Teva Provides Update on Generic Aciphex Litigation
  6. GERD :: New reflux guidelines released
  7. GERD :: Study demonstrates long-term durability of Plicator procedure in GERD
  8. GERD :: Acidity medication increases hip fracture risks
  9. GERD :: Obesity linked to acid reflux disease
  10. GERD :: Fatty foods, alcohol and overeating are triggers for acid reflux

»»   HIV :: Boehringer Ingelheim initiates international head-to-head HIV/AIDS trial
««   Antibiotic :: Teva Announces Approval and Shipment of Generic Omnicef Capsules and POS

Tools
Daily calorie need
Homeo tips
Homeo softwares
Associations
NHMC Alumni
IFH
PHS
Vital Informer
Articles & news
Education
Homeo articles
Homeopathy cases
Homeopathic Remedies
You
Authors
Submit article
Your account
Testimonials
About
About us
Advertisers
Advertising
Linking us
Disclaimer
Privacy policy

The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com